You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Staurosporine


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Staurosporine?

Staurosporine is an investigational drug.

There have been 31 clinical trials for Staurosporine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 22nd 2017.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Sidney Kimmel Comprehensive Cancer Center.

There are five hundred and seventy-nine US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Staurosporine
TitleSponsorPhase
Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaFred Hutchinson Cancer Research CenterPhase 1
Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaOregon Health and Science UniversityPhase 1
Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaPfizerPhase 1

See all Staurosporine clinical trials

Clinical Trial Summary for Staurosporine

Top disease conditions for Staurosporine
trials02468101214LeukemiaLeukemia, Myeloid, AcuteLeukemia, MyeloidNeoplasms[disabled in preview]
Top clinical trial sponsors for Staurosporine
trials051015202530National Cancer Institute (NCI)University Health Network, TorontoSidney Kimmel Comprehensive Cancer Center[disabled in preview]

See all Staurosporine clinical trials

US Patents for Staurosporine

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Staurosporine ⤷  Subscribe Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC) ⤷  Subscribe
Staurosporine ⤷  Subscribe Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Subscribe
Staurosporine ⤷  Subscribe Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN) ⤷  Subscribe
Staurosporine ⤷  Subscribe Combined application of isothiocyanate compound and anti-cancer medicine JC (Wuxi) Company, Inc. (Wuxi, Jiangsu, CN) ⤷  Subscribe
Staurosporine ⤷  Subscribe Molecular constructs with targeting and effector moieties ⤷  Subscribe
Staurosporine ⤷  Subscribe Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Subscribe
Staurosporine ⤷  Subscribe Efficient transport into white blood cells Xigen Inflammation Ltd. (Limassol, CY) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 7 of 7 entries

International Patents for Staurosporine

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Staurosporine Australia AU2012322660 2031-10-11 ⤷  Subscribe
Staurosporine Australia AU2017228527 2031-10-11 ⤷  Subscribe
Staurosporine Canada CA2851788 2031-10-11 ⤷  Subscribe
Staurosporine Canada CA3173988 2031-10-11 ⤷  Subscribe
Staurosporine European Patent Office EP2766355 2031-10-11 ⤷  Subscribe
Staurosporine European Patent Office EP3799871 2031-10-11 ⤷  Subscribe
Staurosporine World Intellectual Property Organization (WIPO) WO2015148714 2034-03-25 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 7 of 7 entries

Staurosporine: A Powerful Drug Candidate with Promising Development and Market Projections

Introduction to Staurosporine

Staurosporine, a potent antiproliferative agent, has been a significant focus in the field of drug discovery and cancer research since its discovery in 1977. Initially isolated from a soil sample by scientists from the Kitasato Institute in Japan, Staurosporine is renowned for its ability to inhibit protein kinases, thereby inducing cell death via intrinsic apoptotic pathways[1].

Historical Significance and Contributions

Staurosporine was the first protein kinase inhibitor to be detected and has played a crucial role in the development of numerous anti-cancer derivatives. Despite its native form being too potent and non-specific for direct clinical use in humans, it has spearheaded the 'Compound first, Bioactivity second' revolution in the 1980s. This approach has led to the approval of 73 small molecule kinase inhibitor drugs by the FDA as of September 2021, with hundreds more in advanced clinical trials[1].

Mechanism of Action

Staurosporine's mechanism involves the inhibition of protein kinases, which are critical enzymes in cell signaling pathways. By blocking these kinases, Staurosporine disrupts cellular processes, leading to cell cycle arrest and apoptosis, particularly in tumor cells. This action is evident in various studies, including those using HeLa cells, where Staurosporine treatment results in distinct phases of cellular stress and eventual cell death[1].

Current Research and Applications

Cancer Research

Staurosporine continues to be a valuable tool in cancer research. Advanced drug delivery systems, such as encapsulating drugs within liposomal nanoparticles, are being explored to reduce off-target side effects while maintaining the drug's potency against solid tumors. Nanolive's innovative imaging platform has been instrumental in evaluating the toxicity and efficacy of Staurosporine and its delivery systems, providing detailed insights into the kinetics of Staurosporine-induced cell death[1].

Acanthamoeba Keratitis Treatment

Recent studies have also explored Staurosporine as a potential treatment for Acanthamoeba keratitis, a serious eye infection. Using an ex vivo mouse cornea model, researchers have shown that Staurosporine can prevent the adhesion and invasion of Acanthamoeba trophozoites into the corneal epithelium, suggesting its potential as a new line of eye drops for treating this condition[3].

Nasal Polyp Treatment

Another area of research involves the use of Staurosporine in treating nasal polyps. Isolated from a Streptomyces sp. SNC087 strain, Staurosporine has been shown to inhibit the expression of fibrotic markers in nasal polyp-derived fibroblasts, indicating its potential in reducing fibrosis associated with nasal polyps[4].

Market Projections

The market for Staurosporine is anticipated to experience significant growth from 2022 to 2030. Here are some key market projections:

Global Market Size

The Staurosporine market is projected to grow at an estimated CAGR, with the market size expected to increase substantially by 2030. This growth is driven by the increasing applications of Staurosporine in research and medicine[2][5].

Research and Development

The technological advancements in drug delivery systems and the ongoing research in various therapeutic areas are key drivers of the Staurosporine market. The development of new formulations and delivery methods, such as liposomal nanoparticles, is expected to enhance the efficacy and safety of Staurosporine-based treatments[1].

Clinical Trials and Approvals

With numerous small molecule kinase inhibitors already approved and many more in clinical trials, the market is poised for further expansion. The FDA approvals and the advancement of these drugs through clinical phases are critical indicators of the market's potential growth[1].

Technological Advancements

Advanced Imaging Techniques

Nanolive’s label-free and non-invasive imaging platform has revolutionized the evaluation of Staurosporine’s effects on cells. This technology allows for continuous imaging of cells with sub-cellular resolution, providing detailed insights into the dynamics and kinetics of cell death induced by Staurosporine[1].

Drug Delivery Systems

The encapsulation of Staurosporine within liposomal nanoparticles is a significant advancement. This method reduces off-target side effects while maintaining the drug's potency, making it a promising approach for treating solid tumors[1].

Challenges and Future Directions

Toxicity and Specificity

Despite its potential, Staurosporine's native form is too potent and non-specific for direct clinical use. Future research is focused on developing analogues and delivery systems that can mitigate these issues while retaining the drug's therapeutic efficacy[1].

Ethical and Regulatory Considerations

The use of in vivo animal models in drug development is fraught with ethical issues. Advanced imaging techniques and in vitro models are being developed to address these concerns and streamline the drug development process[1].

Key Takeaways

  • Historical Significance: Staurosporine was the first protein kinase inhibitor discovered and has been instrumental in cancer research.
  • Mechanism of Action: Inhibits protein kinases, leading to cell cycle arrest and apoptosis.
  • Current Applications: Being explored for cancer, Acanthamoeba keratitis, and nasal polyp treatments.
  • Market Projections: Expected significant growth driven by research and technological advancements.
  • Technological Advancements: Advanced imaging techniques and drug delivery systems are enhancing the efficacy and safety of Staurosporine.

FAQs

Q: What is Staurosporine and where was it discovered?

A: Staurosporine is a potent antiproliferative agent discovered in 1977 from a soil sample by scientists from the Kitasato Institute in Japan.

Q: Why is Staurosporine not used directly in its native form for clinical purposes?

A: Staurosporine is too potent and non-specific in its native form, making it unsuitable for direct clinical use.

Q: What are some of the current applications of Staurosporine in research?

A: Staurosporine is being explored for treating cancer, Acanthamoeba keratitis, and nasal polyps.

Q: How does Nanolive’s imaging platform contribute to the development of Staurosporine?

A: Nanolive’s platform provides label-free and non-invasive imaging, allowing for detailed analysis of the kinetics of Staurosporine-induced cell death.

Q: What are the market projections for Staurosporine?

A: The market is expected to grow significantly from 2022 to 2030, driven by its applications in research and medicine.

Sources

  1. Nanolive: Staurosporine-induced cell death - Nanolive
  2. Extrapolate: Staurosporine Global Market Status and Trend Report 2022-2030
  3. MDPI: Staurosporine as a Potential Treatment for Acanthamoeba Keratitis Using Mouse Cornea as an Ex Vivo Model
  4. MDPI: The Inhibition Effect and Mechanism of Staurosporine Isolated from Streptomyces sp. SNC087 Strain on Nasal Polyp
  5. GitHub: Staurosporine Market Global Outlook and Forecast 2022-2028

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.